What Cogent Biosciences does

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors for genetically defined diseases, with a primary focus on KIT-driven cancers and hematologic disorders. Founded in 2014/2015 and headquartered in Waltham, Massachusetts with a discovery facility in Boulder, Colorado, the company is publicly traded on NASDAQ (COGT). Its lead asset bezuclastinib (CGT9486) is a highly selective KIT inhibitor designed against the KIT D816V mutation, with positive pivotal data across three indications: NonAdvanced Systemic Mastocytosis (SUMMIT), Advanced Systemic Mastocytosis (APEX), and second-line GIST in combination with sunitinib (PEAK). Two NDAs have been accepted with PDUFA dates in November and December 2026, and a third NDA for AdvSM is planned for mid-2026.

The broader pipeline includes CGT1145, a JAK2 V617F mutant-selective inhibitor (>100x selectivity over wild-type JAK2) for myelofibrosis and related myeloproliferative neoplasms, plus preclinical-stage programs targeting KRAS(ON/OFF), wild-type-sparing PI3Kα, and ErbB2/HER2. Cogent is pre-revenue with no product sales and operates a pre-commercial model relying on future pharmaceutical product sales following FDA approval. Revenue mechanics will flow through traditional specialty pharmacy and oncology distribution channels to oncology and hematology HCPs, with projected bezuclastinib revenues of $170.5M in FY27 scaling to $678.6M by FY30 per Raymond James estimates. The go-to-market strategy is enterprise field sales targeting specialty centers treating rare disease patients.

Cogent has raised over $1.5 billion since inception across equity offerings, PIPEs, and non-dilutive debt, ending 2025 with $900.8M in cash and marketable securities (runway into 2028). The November 2025 concurrent offerings of common stock and $200M convertible notes due 2031 represent the largest single capital raise to date. Market capitalization reached approximately $5.29B in early 2026, reflecting strong investor validation of the bezuclastinib opportunity and pipeline breadth.

Name

Cogent Biosciences

Legal name

Cogent Biosciences, Inc.

Website

https://cogentbio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Cogent Biosciences is a clinical-stage biotechnology company developing precision small-molecule kinase inhibitors, led by bezuclastinib for KIT-driven systemic mastocytosis and GIST. Pre-revenue, it is building a commercial organization for a planned H2 2026 launch targeting oncology and hematology specialists.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

akta.pro secondary industries

Lead Optimization & Preclinical Candidate Selection (HLAIALAB), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Precision oncology therapeutics
• Kinase inhibitor development
• Biopharmaceutical drug discovery
• Small molecule cancer therapy
• Targeted rare disease treatment

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Pharmaceutical product sales: Pre-commercial biotech company expecting to generate revenue from commercialization of bezuclastinib and other drug candidates following FDA approval. Projected revenues of $170.5 million in FY27 growing to $678.6 million by FY30.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Cogent Biosciences is a clinical-stage biotechnology company developing precision small molecule therapeutics that target the underlying genetic drivers of cancer and rare diseases. Its lead asset, bezuclastinib (CGT9486), is a selective KIT inhibitor being advanced through pivotal trials for NonAdvanced Systemic Mastocytosis (NonAdvSM), Advanced Systemic Mastocytosis (AdvSM), and Gastrointestinal Stromal Tumors (GIST), with three NDA submissions planned and a commercial launch targeted for H2 2026. Earlier-stage pipeline assets include a JAK2 V617F inhibitor (CGT1145), an ErbB2/HER2 inhibitor, a wild-type-sparing PI3Kα inhibitor, and a pan-KRAS inhibitor.

Differentiator

Problem solved

Functional benefit

Products and services

• Bezuclastinib (CGT9486) Investigational highly selective and potent oral KIT inhibitor targeting the KIT D816V mutation; being developed for NonAdvanced Systemic Mastocytosis, Advanced Systemic Mastocytosis, and second-line GIST (in combination with sunitinib). Designed for patients with KIT-driven hematologic and oncologic diseases.
• CGT1145 (JAK2 V617F Inhibitor) Investigational potential best-in-class JAK2 V617F mutant-selective inhibitor (>100x selective over JAK2 WT) in preclinical development for myelofibrosis, polycythemia vera and essential thrombocythemia.
• Pan-KRAS Inhibitor

Quantifiable outcome

• 56% relative improvement in Total Symptom Score with -32.0 point mean reduction
• +6 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• The Life Raft GroupcoreStrategic or Co-development PartnerPatient advocacy partnership supporting GIST patients through the GIST Hope Mosaic photo mosaic project honoring those impacted by GIST, and collaboration on patient education resources.
• The Mast Cell Disease SocietycoreStrategic or Co-development PartnerPatient advocacy partnership creating the Systemic Mastocytosis Mosaic featuring stories of individuals impacted by SM and those who support them, with global community contributions.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Blueprint Medicines: Blueprint Medicines markets AYVAKIT (avapritinib), the leading approved KIT D816V inhibitor for advanced and non-advanced systemic mastocytosis, directly competing with Cogent's bezuclastinib in the same indication and prescriber base.
• Deciphera Pharmaceuticals: Deciphera developed Qinlock (ripretinib) for fourth-line GIST, making it a direct competitor to bezuclastinib in the GIST indication, particularly for imatinib-resistant patients that Cogent's PEAK trial addresses.
• Kura Oncology: Kura Oncology is developing tipifarnib, a farnesyl transferase inhibitor for HRAS-mutant and other solid tumors, with similar precision oncology positioning and biomarker-driven development approach targeting genetically defined cancers.

Emerging players

• Syndax Pharmaceuticals: Syndax is developing revumenid for chronic Graft-versus-Host Disease and menin inhibitors for AML, sharing Cogent's precision medicine approach with strong board overlap (Arlene Morris sits on both boards).
• Ajax Therapeutics: Ajax Therapeutics is developing next-generation JAK2 inhibitors for myeloproliferative neoplasms, directly competing with Cogent's CGT1145 JAK2 V617F program in the same target indication.
• Schrödinger: Schrödinger uses computational physics-based platform to discover and develop precision medicines targeting genetically defined diseases, sharing Cogent's precision oncology philosophy but using a distinct drug discovery modality.

Broad incumbents

• Incyte: Incyte markets ruxolitinib (JAKAFI), the established JAK1/2 inhibitor used in myelofibrosis and polycythemia vera, making it a relevant competitor for Cogent's CGT1145 JAK2 V617F selective inhibitor pipeline program.
• Bristol-Myers Squibb: BMS markets PIVYA (pirtobrutinib) and has a broad oncology portfolio, plus historical GIST franchise (sprycel), making it a relevant broad incumbent for benchmarking in oncology market access and competitive dynamics.
• Pfizer: Pfizer markets sunitinib (Sutent), the standard-of-care second-line GIST therapy used as comparator in Cogent's PEAK trial, and is the acquirer of Array BioPharma where multiple Cogent executives previously worked.
• Novartis: Novartis markets imatinib (Gleevec), the first-line GIST therapy and the patient population from which Cogent's bezuclastinib combination treatment in PEAK addresses.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CogentBio
• LinkedInlinkedin.com/company/cogentbiosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles28 records

Funding overview

Funding rounds14 records

Investors30 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cogent Biosciences